Abstract 2342
Background
The FIRSTANA trial compared docetaxel 75mg/m2 Q3W (D75), cabazitaxel 20mg/m2 Q3W (C20) and cabazitaxel 25mg/m2 Q3W (C25) in patients with chemo-naive mCRPC (Oudard 2017). FIRSTANA enrolled patients regardless of presence of disease-related symptoms. This post-hoc analysis of FIRSTANA evaluates the influence of progression type on outcomes.
Methods
Patient outcomes (OS, PSA response [confirmed PSA decline from baseline ≥ 50%] and radiological PFS [rPFS]) were analyzed according to progression type at randomization. Progression at randomization was defined as follows: PSA progression only (PSA-p) with no radiological progression (Radio-p) and no pain, Radio-p (± PSA-p, no pain), pain progression (mean Present Pain Intensity ≥2 and/or mean analgesic score ≥ 10 over the 7 days prior to randomization (±PSA-p, ±Radio-p).
Results
PSA-p, Radio-p and Pain-p were present in 34.4%, 23.2% and 42.3% of patients at randomization, respectively. Pain progression at initiation of chemotherapy was associated with features of aggressive disease and a shorter OS. Lower activity of C20 than C25 and D75 was observed in patients with Pain-p.Table:
859P
Progression type | ||||
---|---|---|---|---|
PSA-p N = 362 | Radio-p N = 244 | Pain-p N = 445 | Global p° | |
- PSA decrease ≥ 50% - Overall - D75 - C20 - C25 | 69.0% 67.4% 71.0% 69.0% | 69.8% 65.8% 66.2% 78.3% | 58.0% 62.2% 49.3% 63.0% | P = 0.003 P = 0.70 P = 0.002 P = 0.21 |
-rPFS, median [95% CI]* - Overall - D75 - C20 - C25 | 16.5 [14.3; 18.9] 13.5 [11.3; 16.7] 19.7 [14.3; 26.5] 18.2 [14.2; 22.6] | 12.1 [11.2; 14.4] 11.3 [9.7; 14.4] 13.4 [10.6; 22.8] 11.4 [10.1; 15.7] | 10.8 [9.3;11.6] 11.4 [8.8; 13.9] 9.1 [7.6; 10.9] 11.1 [9.7; 12.8] | p < 0.001 p = 0.13 p < 0.001 p = 0.001 |
OS, median [95% CI]* - Overall - D75 - C20 - C25 | 27.7 [25.4;31.2] 29.0 [22.6; 36.6] 30.0 [24.9; NR] 26.5 [24.0; 31.6] | 30.6 [26.8;34.3] 28.4 [22.0; 34.1] 32.1 [27.9; 41.4] 29.7 [24.0; 38.5] | 18.5 [16.8; 20.6] 20.3[16.5;24.3] 16.5[14.3; 19.1] 20.4[17.0;25.3] | p < 0.001 p = 0.003 p < 0.001 p = 0.031 |
in months, NR: not reached; °Log rank test for rPFS and OS, CMH test adjusted on stratification factors
Conclusions
Most patients in FIRSTANA had pain progression at randomization and this factor was associated with worse OS. In this post-hoc, subgroup analysis, C20 appeared less active than D75 and C25 in men with baseline pain progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nicolas Delanoy.
Funding
Sanofi.
Disclosure
N. Delanoy: Travel / Accommodation / Expenses: Sanofi; Honoraria (self): Tesaro; Honoraria (self): MSD. D. Robbrecht: Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy: Bayer. K. Fizazi: Honoraria (self): Amgen; Honoraria (self): Astellas; Honoraria (self): AstraZeneca; Honoraria (self): Bayer; Honoraria (self): Clovis; Honoraria (self): CureVac; Honoraria (self): Essa; Honoraria (self): Genentech; Honoraria (self): Janssen; Honoraria (self): MSD; Honoraria (self): Orion; Honoraria (self): Sanofi. F. Mercier: Honoraria (self): Sanofi; Honoraria (self): AstraZeneca; Shareholder / Stockholder / Stock options, Stat Process is a CRO providing statistical services to various companies: Stat Process. O. Sartor: Shareholder / Stockholder / Stock options: Eli Lilly; Shareholder / Stockholder / Stock options: GlaxoSmithKline; Shareholder / Stockholder / Stock options: Noria; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy: Bellicum; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Johnson &Johnson; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Dendreon; Advisory / Consultancy, Research grant / Funding (institution): Endocyte; Advisory / Consultancy: Constellation Pharmaceuticals; Advisory / Consultancy: Advanced Accelerator Applications; Advisory / Consultancy: Pfizer; Advisory / Consultancy: BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: Bavarian Nordic; Advisory / Consultancy: Oncogenex; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Astellas; Advisory / Consultancy, Travel / Accommodation / Expenses: Progenics. R. de Wit: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Genentech. S. Oudard: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Astellas; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen; Honoraria (self): Bayer; Honoraria (self): Pfizer; Honoraria (self): MSD; Honoraria (self): Novartis; Honoraria (self): BMS; Honoraria (self): Ipsen.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract